Alexion Pharmaceuticals Inc (ALXN): Heidi L Wagner , SVP, Global Government Affairs of Alexion Pharmaceuticals Inc sold 53 shares on May 13, 2016. The Insider selling transaction was reported by the company on May 13, 2016 to the Securities and Exchange Commission. The shares were sold at $138.65 per share for a total value of $7,348.45 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 5, 2016, David Hallal (CEO) sold 1,414 shares at $136.04 per share price.On Mar 4, 2016, Julie O’neill (EVP. Global Operations) sold 651 shares at $149.55 per share price.Also, On Mar 1, 2016, Heidi L Wagner (SVP, Global Government Affairs) sold 547 shares at $138.91 per share price.On Mar 1, 2016, Saqib Islam (EVP, Chief Strat & Port. Off.) sold 905 shares at $138.91 per share price.
Alexion Pharmaceuticals: On Tuesday, May 10, 2016 heightened volatility was witnessed in Alexion Pharmaceuticals which led to swings in the share price. The shares opened for trading at $144.75 and hit $145.7 on the upside , eventually ending the session at $145.48, with a gain of 1.37% or 1.96 points. The heightened volatility saw the trading volume jump to 9,12,053 shares. The 52-week high of the share price is $208.88 and the company has a market cap of $32,590 M . The 52-week low of the share price is at $124.16.
Company has been under the radar of several Street Analysts.Alexion Pharmaceuticals is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 180 from a previous price target of $175 .The Rating was issued on May 9, 2016.Alexion Pharmaceuticals is Downgraded by Robert W. Baird to Neutral while Lowering the Price Target of the company shares to $ 170 from a previous price target of $221 . Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Mar 8, 2016.Alexion Pharmaceuticals is Initiated by Citigroup to Buy and the brokerage firm has set the Price Target at $165. The Rating was issued on Feb 25, 2016.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.